• FDA Fast-tracks Magrolimab for Treatment of Myelodysplastic Syndrome, Acute Myeloid Leukemia
  • First-line Imfinzi-Chemo Therapy Extends Survival of Patients with Aggressive Lung Cancer, Phase 3 Trial Shows
  • Keytruda and Inlyta Combo Approved in Europe for Untreated Advanced Kidney Cancer
  • Nanotechnology May Help Get Immunotherapy Into the Brain, Mouse Study Says
  • FDA Grants Orphan Drug Status to BioXcel’s BXCL701 as Potential AML Treatment
  • Health Canada and European Commission OK Tecentriq-Chemo Combo for Aggressive Lung Cancer
  • Trial of Targeted Radiation Therapy, CLR 131, in Children with Advanced Cancers Moving to Higher Dose
  • Imfinzi-Tremelimumab Combo Fails to Prolong Overall Survival in Metastatic NSCLC, Phase 3 Trial Shows
  • Pexa-Vec Combo Unlikely to Benefit Advanced Liver Cancer Patients in Phase 3 Trial, Monitoring Group Says
  • $102.2M Pelotonia Gift to Help Establish Immuno-Oncology Institute at OSU
  • EU Committee Recommends Orphan Drug Status for Ziopharm’s IL-12 Gene Therapy for Glioblastoma
  • Study Explains Checkpoint Inhibitors’ Efficacy in PD-L1 Negative Tumors